Disease relevance of Trisulfa

• At present, therapy for toxoplasmic encephalitis (TE) is the combination of pyrimethamine with sulfadiazine or trisulfapyrimidines [1].
• We recommend 6 weeks of high doses of pyrimethamine and sulfadiazine (or trisulfapyrimidines) as primary therapy for the acute disease followed by daily administration of reduced doses of these drugs [2].
• The only complication was skin rash secondary to trisulfapyrimidine therapy, in four cases [3].
• Therapeutic usefulness of combination therapy with oral penicillin G and trisulfapyrimidine in the treatment of acute upper respiratory tract infections [4].
• Treatment for toxoplasmosis includes pyrimethamine with sulfadiazine or trisulfapyrimidine; congenital herpes simplex virus infection is treated with acyclovir [5].

High impact information on Trisulfa

• The bioavailability of seven commercial trisulfapyrimidine suspensions was studied in 14 adult male volunteers [6].
• Preparation of superior thin-layer chromatograms for quantitative in situ densitometry by nonequilibrated development. I. Trisulfapyrimidines: sulfadiazine, sulfamerazine, and sulfamethazine [7].

References